Treatment
Lorlatinib clinical trials
We’re tracking 14 recruiting studies that include Lorlatinib, each written for real people, not researchers, below.
Recruiting studies
- NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Aurora, ColoradoAges 1–21 - NCT06378892RecruitingPhase 2
Study of chemo plus lorlatinib for ALK+ lung cancer
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
AvianoAges 18 years+ - NCT07784959RecruitingPhase 1
Study of NXP900 with lorlatinib for ALK-positive lung cancer
This study tests a new drug called NXP900 in combination with lorlatinib for people with ALK-positive lung cancer who have already been treated with lorlatinib and tolerated it well. The goal is to see if this combination is safe and effective.
Fairfax, VirginiaAges Any age - NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Birmingham, AlabamaAges 12 months–30 years - NCT07415005RecruitingPhase 2
Lorlatinib and local therapy for ALK-positive lung cancer
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
Houston, TexasAges 18 years+ - NCT06487078Recruiting
Study of Lorlatinib for untreated ALK-positive lung cancer
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
Paris, ParisAges 18 years+ - NCT07374614Recruiting
Study of iruplinalkib after lorlatinib for ALK-positive lung cancer
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
Shenzhen, GuangdongAges 18 years+ - NCT06876675Enrolling by invitation
Lorlatinib and high cholesterol in ALK+ lung cancer
This study looks at how the drug Lorlatinib affects cholesterol levels in people with ALK-positive non-small cell lung cancer. It aims to understand and manage these side effects better.
BeijingAges 18–80 - NCT07617337RecruitingPhase 1
AQUA07 for ALK-positive lung cancer
This trial tests a new drug called AQUA07 for patients with ALK-positive lung cancer that has spread or cannot be removed with surgery. You must have already tried at least one other ALK-targeting drug (but not just crizotinib alone) to be eligible.
Nagoya, Aichi-kenAges 18 years+ - NCT06092086RecruitingPhase 2
Lorlatinib for first-line treatment of ALK-positive lung cancer
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Guangzhou, GuangdongAges 18 years+ - NCT06361589Recruiting
Lorlatinib for advanced ALK-positive lung cancer
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
Chengdu, SichuanAges 18 years+ - NCT06532149Recruiting
Sexual health and erectile function in men with lung cancer
This study looks at how lung cancer and its treatments affect men's sexual health, including erectile function and hormone levels. If you are a man with advanced lung cancer and are sexually active, researchers want to learn about your experiences and test results.
RomeAges 18–75 - NCT02925234RecruitingPhase 2
Basket trial of reused cancer drugs matched to tumor markers
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
AlkmaarAges 18 years+ - NCT07633626Recruiting
Vortioxetine for thinking problems from ALK lung cancer treatment
This trial tests whether a medication called vortioxetine can help improve memory, focus, and thinking problems caused by lorlatinib, a drug used to treat ALK-positive lung cancer. You would take vortioxetine alongside your current cancer treatment to see if it helps your brain function.
BogotáAges 18 years+
What Lorlatinib is being studied for
Conditions with recruiting Lorlatinib studies.
Common questions
- Are there clinical trials studying Lorlatinib?
- Yes. Clin2 currently lists 14 recruiting studies that include Lorlatinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Lorlatinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Lorlatinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Lorlatinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.